CoChat

Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis

Open access

The DOI matches its Crossref record; 312 of the 326 references it cites were found in a registry or an index; 153 of the 280 sources its claims cite were checked for support.

Abstract

Drug delivery to solid tumors is challenged by multiple physiological barriers arising from the tumor microenvironment, including dense extracellular matrix, cellular heterogeneity, hypoxic gradients, and elevated interstitial fluid pressure. These features hinder the uniform distribution and accumulation of therapeutics, reducing treatment efficacy. Despite their widespread use, conventional two-dimensional monolayer cultures fail to reproduce these complexities, contributing to the poor translational predictability of many preclinical candidates. Three-dimensional multicellular tumor spheroids have emerged as more representative in vitro models that capture essential features of tumor architecture, stromal interactions, and microenvironmental resistance mechanisms. Spheroids exhibit spatially organized regions of proliferation, quiescence, and hypoxia, and can incorporate non-tumor cells to mimic tumor–stroma crosstalk. Advances in spheroid analysis now enable detailed evaluation of drug penetration, cellular migration, cytotoxic response, and molecular gradients using techniques such as optical and confocal imaging, large-particle flow cytometry, biochemical viability assays, and microfluidic integration. By combining physiological relevance with analytical accessibility, spheroid models support mechanistic studies of drug transport and efficacy under tumor-like conditions. Their adoption into routine preclinical workflows has the potential to improve translational accuracy while reducing reliance on animal models.

Overview

CoChat Summary

TL;DR

This review argues that 3D multicellular tumor spheroids better capture tumor microenvironment barriers than 2D monolayers and can be analyzed with imaging, flow cytometry, viability assays, and microfluidics. It synthesizes TME biology, spheroid features, and analytical strategies to improve preclinical drug testing.

Key findings

  • Spheroids reproduce spatial gradients seen in solid tumors: proliferative outer rim, quiescent intermediate zone, and hypoxic/necrotic core; these gradients typically emerge when spheroids exceed ~500 μm in diameter, core pH ranges between 6.5 and 7.2, and growth plateaus at approximately 600–800 µm.
  • Stromal and ECM incorporation increases drug resistance: breast tumor spheroids with higher fibroblast content showed decreased dextran diffusion and diminished doxorubicin cytotoxicity, while pancreatic triple co-cultures of tumor cells, fibroblasts, and endothelial cells demonstrated greater drug resistance than spheroids lacking either stromal component.
  • Spheroid gene expression more closely resembles solid tumors than monolayers: in melanoma spheroids, over 100 transcripts were upregulated and approximately 70 downregulated compared with monolayers; a meta-analysis of NCI-60 monolayers versus clinical tumor samples found about 30% of ~7000 genes with altered expression.
  • Analytical approaches include brightfield/confocal/electron/SHG microscopy, large-particle flow cytometry, FLIM-BrdU, and microfluidic systems; large-particle flow cytometry tracked fibroblast migration toward the spheroid core by day 5 and endothelial cell clustering near fibroblasts.

Methods

  • Narrative review; no systematic search strategy, inclusion criteria, or meta-analysis is described.
  • Synthesizes published literature on TME components, limitations of 2D and in vivo models, spheroid biology, and techniques for spheroid analysis.
  • No primary experimental data or sample; findings are drawn from cited studies and illustrative examples.

Limitations

  • The paper does not state limitations.
  • Evident from the review format: no systematic search or quantitative synthesis is reported, so literature coverage and conclusions may be non-exhaustive.
  • Evident from the text: many cited findings come from specific cell lines and tumor models, and the review does not systematically assess reproducibility or generalizability across all tumor types.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/cells14100732

Cites

312 of 312 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Schematic representation of the tumor microenvironment (TME) and its key components. (A) Hypoxia: Resulting from disorganized and inefficient vasculature, leading to oxygen deprivation in the tumor core and promoting survival adaptations and therapy resistance. (B) Tumor cells: The central malignant population that interacts with and reshapes the surrounding microenvironment. (C) Extracellular matrix (ECM): A structurally and biochemically complex network composed of fibrous proteins (e.g., collagen), structural glycoproteins (such as SPARC), proteoglycans, and glycosaminoglycans, like hyaluronic acid. These components not only provide mechanical support but also modulate cellular adhesion, migration, and signal transduction. (D) Immune cells: Includes T cells, B cells, macrophages, dendritic cells, and NK cells that exhibit both anti-tumor and immunosuppressive roles. (E) Angiogenesis: Aberrant formation of blood vessels induced by tumor and stromal signaling; supports oxygen/nutrient delivery and facilitates metastasis via increased vascular permeability. (F) Inflammatory cytokines: Soluble mediators such as IL-6, TNF-α, TGF-β, and VEGF that promote chronic inflammation, immune suppression, angiogenesis, and stromal activation. (G) Stromal components: Includes cancer-associated fibroblasts, adipocytes, mesenchymal stem cells, tumor associated endothelial cells that regulate ECM remodeling, metabolic support, and immune modulation.
Figure 1 Schematic representation of the tumor microenvironment (TME) and its key components. (A) Hypoxia: Resulting from disorganized and inefficient vasculature, leading to oxygen deprivation in the tumor core and promoting survival adaptations and therapy resistance. (B) Tumor cells: The central malignant population that interacts with and reshapes the surrounding microenvironment. (C) Extracellular matrix (ECM): A structurally and biochemically complex network composed of fibrous proteins (e.g., collagen), structural glycoproteins (such as SPARC), proteoglycans, and glycosaminoglycans, like hyaluronic acid. These components not only provide mechanical support but also modulate cellular adhesion, migration, and signal transduction. (D) Immune cells: Includes T cells, B cells, macrophages, dendritic cells, and NK cells that exhibit both anti-tumor and immunosuppressive roles. (E) Angiogenesis: Aberrant formation of blood vessels induced by tumor and stromal signaling; supports oxygen/nutrient delivery and facilitates metastasis via increased vascular permeability. (F) Inflammatory cytokines: Soluble mediators such as IL-6, TNF-α, TGF-β, and VEGF that promote chronic inflammation, immune suppression, angiogenesis, and stromal activation. (G) Stromal components: Includes cancer-associated fibroblasts, adipocytes, mesenchymal stem cells, tumor associated endothelial cells that regulate ECM remodeling, metabolic support, and immune modulation.CC BY · PubMed Central
Figure 2 Spheroid-based tumor models recapitulate key features of the in vivo tumor microenvironment. (A) Cellular heterogeneity and intracellular signaling: Tumor spheroids incorporate diverse cell types, such as cancer cells, fibroblasts, and immune cells, enabling crosstalk via paracrine signaling pathways that reflect in vivo cellular interactions. (B) Spatial cellular organization: Gradients of proliferating, quiescent, and necrotic zones develop radially within the spheroid, mirroring the spatial compartmentalization observed in solid tumors. (C) Deposition of extracellular matrix (ECM): Stromal and tumor cells within spheroids secrete ECM components like collagen and fibronectin, contributing to matrix stiffness, structural integrity, and regulation of therapeutic penetration. (D) Physiological flow-based spheroid system: Integration of spheroids within microfluidic platforms facilitates the simulation of interstitial flow and dynamic nutrient exchange, enhancing physiological relevance and modeling of drug transport. (E) Comparable gene expression patterns: Schematic representation demonstrating how spheroids exhibit transcriptional profiles more similar to in vivo tumors than monolayer cultures, providing a more predictive model for evaluating therapeutic response and resistance.
Figure 2 Spheroid-based tumor models recapitulate key features of the in vivo tumor microenvironment. (A) Cellular heterogeneity and intracellular signaling: Tumor spheroids incorporate diverse cell types, such as cancer cells, fibroblasts, and immune cells, enabling crosstalk via paracrine signaling pathways that reflect in vivo cellular interactions. (B) Spatial cellular organization: Gradients of proliferating, quiescent, and necrotic zones develop radially within the spheroid, mirroring the spatial compartmentalization observed in solid tumors. (C) Deposition of extracellular matrix (ECM): Stromal and tumor cells within spheroids secrete ECM components like collagen and fibronectin, contributing to matrix stiffness, structural integrity, and regulation of therapeutic penetration. (D) Physiological flow-based spheroid system: Integration of spheroids within microfluidic platforms facilitates the simulation of interstitial flow and dynamic nutrient exchange, enhancing physiological relevance and modeling of drug transport. (E) Comparable gene expression patterns: Schematic representation demonstrating how spheroids exhibit transcriptional profiles more similar to in vivo tumors than monolayer cultures, providing a more predictive model for evaluating therapeutic response and resistance.CC BY · PubMed Central
Figure 3 Representative analytical platforms and their uses to characterize spheroid structure and function.
Figure 3 Representative analytical platforms and their uses to characterize spheroid structure and function.CC BY · PubMed Central
Figure 4 Large particle flow cytometer (COPAS Vision) analysis of multicellular spheroids. (A) COPAS Vision dot plots representing diameter measurement Time of Flight (TOF) vs. Optical density (EXT) (B) TOF measurements (diameter) of spheroids in microseconds (C) Arbitrary count of Optical density (EXT) (D) Representative profiler plots of signal intensity across individual spheroids Optical density (blue), green fluorescence (green), and red fluorescence (red) for each plot, inset shows corresponding monochrome image of spheroid analyzed. (E) Integral fluorescence to Optical Density ratio—for day 3 and day 5 old H69/AR:HLF co-culture and day 5 old H69/AR:HLF:HUVEC triple co-culture spheroids. Data represents mean ± standard deviation (n > 200). Student t-test * p < 0.01 vs. day 3 H69/AR:HLF, # p < 0.01 vs. day5 H69/AR:HLF spheroid. $ p < day 5 H69/AR:HLF spheroid.
Figure 4 Large particle flow cytometer (COPAS Vision) analysis of multicellular spheroids. (A) COPAS Vision dot plots representing diameter measurement Time of Flight (TOF) vs. Optical density (EXT) (B) TOF measurements (diameter) of spheroids in microseconds (C) Arbitrary count of Optical density (EXT) (D) Representative profiler plots of signal intensity across individual spheroids Optical density (blue), green fluorescence (green), and red fluorescence (red) for each plot, inset shows corresponding monochrome image of spheroid analyzed. (E) Integral fluorescence to Optical Density ratio—for day 3 and day 5 old H69/AR:HLF co-culture and day 5 old H69/AR:HLF:HUVEC triple co-culture spheroids. Data represents mean ± standard deviation (n > 200). Student t-test * p < 0.01 vs. day 3 H69/AR:HLF, # p < 0.01 vs. day5 H69/AR:HLF spheroid. $ p < day 5 H69/AR:HLF spheroid.CC BY · PubMed Central

Verification

Claims the paper makes

92 Valid · 7 Not valid · 43 Not checked · 20 Own results and interpretations

86 more claims · 55 with their cited sources checked

Create a free account to see all 162 claims and to verify the 7 references still open.

See all claims — free account
  • It may state two separate claims as one. 63
  • Probably not a substantial claim. 12

Create a free account to see these claims.

Citations

Cites

Show all 312 references

Research works printed but not linked: 1

  1. Shah S. Development of co-culture spheroid models of drug-resistant carcinomas for the in vitro testing of anti-tumor treatment strategies Doctor of Philosophy Dissertation MCPHS Boston, USA 2024

Cited by

Metadata

Authors
Shah, S., & D’Souza, G. G. M.
Affiliations
Massachusetts College of Pharmacy and Health Sciences (US)
Corresponding author
Shah, Shrey
Venue
Cells
Publisher
MDPI AG
Published
2025-05-17
Volume
14
Issue
10
Pages
732
ISSN
2073-4409 (ISSN-L)
OpenAlex
W4410519085
Cited by
83
References
326
Citations by year
2026: 72 · 2025: 11
FWCI
9.14
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
Keywords
tumor spheroids, tumor microenvironment, solid tumors, drug delivery barriers, extracellular matrix, hypoxia, interstitial fluid pressure, tumor-stroma interactions, 3D tumor models, drug penetration, drug resistance, confocal microscopy, cytotoxicity
MeSH terms
Animals, Humans, Models, Biological, Neoplasms, Spheroids, Cellular, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.